These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 8758918

  • 1. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
    Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M, Fabbro D.
    Cancer Res; 1996 Aug 01; 56(15):3499-507. PubMed ID: 8758918
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.
    Geiger T, Müller M, Dean NM, Fabbro D.
    Anticancer Drug Des; 1998 Jan 01; 13(1):35-45. PubMed ID: 9474241
    [Abstract] [Full Text] [Related]

  • 3. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
    Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI.
    Mol Pharmacol; 1996 Aug 01; 50(2):236-42. PubMed ID: 8700129
    [Abstract] [Full Text] [Related]

  • 4. Technology evaluation: ISIS-3521.
    Li K, Zhang J, Sirois P, Hu Y.
    Curr Opin Mol Ther; 1999 Jun 01; 1(3):393-8. PubMed ID: 11713804
    [Abstract] [Full Text] [Related]

  • 5. Antisense candidates against protein kinase C-alpha designed based on phylogenesis and simulant structure of mRNA.
    Song HF, Tang ZM, Yuan SJ, Zhu BZ, Liu XW.
    Acta Pharmacol Sin; 2003 Mar 01; 24(3):269-76. PubMed ID: 12617778
    [Abstract] [Full Text] [Related]

  • 6. Definition by specific antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes.
    Lee YS, Dlugosz AA, McKay R, Dean NM, Yuspa SH.
    Mol Carcinog; 1997 Jan 01; 18(1):44-53. PubMed ID: 9022812
    [Abstract] [Full Text] [Related]

  • 7. Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells.
    Wang XY, Repasky E, Liu HT.
    Exp Cell Res; 1999 Jul 10; 250(1):253-63. PubMed ID: 10388539
    [Abstract] [Full Text] [Related]

  • 8. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
    Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E.
    Clin Cancer Res; 2002 Aug 10; 8(8):2530-5. PubMed ID: 12171880
    [Abstract] [Full Text] [Related]

  • 9. Antisense oligonucleotides targeting protein kinase C-alpha, -beta I, or -delta but not -eta inhibit lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages: involvement of a nuclear factor kappa B-dependent mechanism.
    Chen CC, Wang JK, Lin SB.
    J Immunol; 1998 Dec 01; 161(11):6206-14. PubMed ID: 9834107
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
    Geiger T, Müller M, Monia BP, Fabbro D.
    Clin Cancer Res; 1997 Jul 01; 3(7):1179-85. PubMed ID: 9815797
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
    Benimetskaya L, Miller P, Benimetsky S, Maciaszek A, Guga P, Beaucage SL, Wilk A, Grajkowski A, Halperin AL, Stein CA.
    Mol Pharmacol; 2001 Dec 01; 60(6):1296-307. PubMed ID: 11723237
    [Abstract] [Full Text] [Related]

  • 12. Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression.
    Perlaky L, Saijo Y, Busch RK, Bennett CF, Mirabelli CK, Crooke ST, Busch H.
    Anticancer Drug Des; 1993 Feb 01; 8(1):3-14. PubMed ID: 8476501
    [Abstract] [Full Text] [Related]

  • 13. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
    Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI.
    Clin Cancer Res; 1999 Nov 01; 5(11):3357-63. PubMed ID: 10589745
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.
    Dean NM, McKay R.
    Proc Natl Acad Sci U S A; 1994 Nov 22; 91(24):11762-6. PubMed ID: 7972137
    [Abstract] [Full Text] [Related]

  • 15. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.
    McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM.
    J Biol Chem; 1999 Jan 15; 274(3):1715-22. PubMed ID: 9880552
    [Abstract] [Full Text] [Related]

  • 16. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT, Monia BP, Kwoh TJ, Dorr FA.
    Curr Opin Mol Ther; 1999 Jun 15; 1(3):372-85. PubMed ID: 11713802
    [Abstract] [Full Text] [Related]

  • 17. Polo-like kinase1, a new target for antisense tumor therapy.
    Elez R, Piiper A, Giannini CD, Brendel M, Zeuzem S.
    Biochem Biophys Res Commun; 2000 Mar 16; 269(2):352-6. PubMed ID: 10708555
    [Abstract] [Full Text] [Related]

  • 18. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
    Monteith DK, Geary RS, Leeds JM, Johnston J, Monia BP, Levin AA.
    Toxicol Sci; 1998 Dec 16; 46(2):365-75. PubMed ID: 10048140
    [Abstract] [Full Text] [Related]

  • 19. Cellular pharmacology of p120 antisense oligodeoxynucleotide phosphorothioate ISIS 3466.
    Saijo Y, Perlaky L, Valdez BC, Wang H, Henning D, Busch H.
    Oncol Res; 1993 Dec 16; 5(8):283-91. PubMed ID: 8012060
    [Abstract] [Full Text] [Related]

  • 20. [Telomerase antisense inhibition and chemotherapeutic combination treatments for the proliferation of endometrial cancer in vitro and in vivo].
    Chen XJ, Zheng W, Chen LL, Chen ZB, Wang SQ.
    Zhonghua Yi Xue Za Zhi; 2004 Oct 17; 84(20):1721-5. PubMed ID: 15569435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.